Related Experiment Video
Updated: Jun 2, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Errors in ADAS-cog administration and scoring may undermine clinical trials results
K Schafer1, S De Santi, L S Schneider
1University of Southern California, San Diego, USA.
Most experienced raters made errors on the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). These ADAS-cog errors can impact clinical trial results by biasing outcomes and increasing score variability.
Area of Science:
- Neuroscience
- Clinical Trials
- Cognitive Assessment
Background:
- The Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) is a standard measure in Alzheimer's disease (AD) clinical trials.
- Concerns exist that administration and scoring errors may obscure accurate treatment effect estimates.
- Formal examinations of ADAS-cog errors are limited.
Purpose of the Study:
- To investigate the frequency and impact of errors made by experienced raters during ADAS-cog administration and scoring.
- To determine if rater errors affect the reliability and validity of ADAS-cog scores in clinical trials.
Main Methods:
- Experienced raters for two AD clinical trials received standardized ADAS-cog administration training.
- Raters' scores from a model ADAS-cog administration were compared to established criterion scores.
- Error analysis focused on identifying types of errors and their correlation with overall scores.
Main Results:
- 80.6% of 72 raters made at least one error, with 18% making three or more.
- Common errors occurred in word finding difficulty (67%), word recognition (22%), and orientation (22%).
- Raters with errors, particularly in word finding, showed significantly different ADAS-cog means and increased score variance compared to those without errors.
Conclusions:
- Most experienced raters commit errors in ADAS-cog administration and scoring.
- These errors can introduce bias and increase variability in ADAS-cog scores, potentially affecting the detection of treatment effects in clinical trials.
- Standardized training and rigorous quality control are crucial for accurate ADAS-cog assessments.
Related Concept Videos
Clinical Trials: Overview
Errors occurring during blood pressure monitoring
Several factors...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Systematic Error: Methodological and Sampling Errors
Sampling errors originate from improper sampling methods or the wrong sample population. These errors can be minimized by refining the sampling strategy. Defective instruments or faulty calibrations are the sources of instrumental...
